• Users Online: 535
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Year : 2012  |  Volume : 3  |  Issue : 2  |  Page : 75-81

A comparison of risk-based outcome of pediatric AML in the first complete remission following treatment with chemotherapy alone: experience from a single Saudi Arabian Institution

1 King Saud Bin Abdulaziz University and Princess Noorah Oncology Center, King Abdulaziz Medical City, Jeddah; Department of Pediatrics, Faculty of Medicine, Umm AlQura University, Makkah, Saudi Arabia
2 King Saud Bin Abdulaziz University and Princess Noorah Oncology Center, King Abdulaziz Medical City, Jeddah, Saudi Arabia
3 King Saud Bin Abdulaziz University and Princess Noorah Oncology Center; King Saud Bin Abdulaziz University and Department of Pathology, King Abdulaziz Medical City, Jeddah, Saudi Arabia

Correspondence Address:
Wasil Jastaniah
Chairman, Princess Noorah Oncology Center, Consultant Pediatric Hematology/Oncology/BMT and Assistant Professor, Umm AlQura University, Makkah King Abdulaziz Medical City, Princess Noorah Oncology Center, P.O.Box 9515 Jeddah 21423
Saudi Arabia
Login to access the Email id

Source of Support: None, Conflict of Interest: None

Rights and PermissionsRights and Permissions

This study retrospectively analyzed 56 consecutive pediatric patients diagnosed with acute myeloid leukemia and treated with chemotherapy alone, according to the modified Medical Research Council10 protocol, in our institution between 1996 and 2012. Patients were stratified according to the cytogenetics and remission status into low-risk, intermediate-risk, high-risk, and unknown-risk groups. There were statistically significant differences in the overall survival (OS) rates between the risk groups (P < 0.0001). The 5-year OS rates were 85% ± 10% for the low-risk group, 65% ± 13% for the intermediate-risk group, and 31% ± 10% for the unknown-risk group. None of the patients in the high-risk group survived for 5-years. The 5-year event-free survival rates were 70% ± 13%, 59% ± 14%, and 31% ± 12% for the low-, intermediate-, and unknown-risk groups, respectively. The differences among these groups were statistically significant (P < 0.0001). These findings are comparable with those reported by studies in Europe and North America, but they differ from those reported in Asia. We conclude that risk-based stratification predicts the outcome of pediatric patients treated with chemotherapy alone and that the survival rates are similar to those in other published studies.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded143    
    Comments [Add]    

Recommend this journal